Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HB0036 in advanced solid tumors
NCT05417321Phase 2Recruiting
- Sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.
- Start
- Aug 2022
- Primary completion
- Aug 2025
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of HB0036 in solid tumor (advanced stage), non-small cell lung cancer (NSCLC), Esophageal Squamous Cell Carcinoma (ESCC) and 6 more, sponsored by Shanghai Huaota Biopharmaceutical Co., Ltd. Primary endpoints: Safety and tolerability up to 12 Months and Maximum Tolerated Dose up to 24 Months. Started Aug 2022; status: recruiting.
02
Drugs
HB0036
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)Esophageal Squamous Cell Carcinoma (ESCC)melanomahepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05417321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05417321.